The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $7.39

Today's change+0.03 +0.41%
Updated July 29 11:25 AM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $7.39

Today's change+0.03 +0.41%
Updated July 29 11:25 AM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc up (U.S.)$0.03

Keryx Biopharmaceuticals Inc is up today by (U.S.)$0.03 or 0.41% to (U.S.)$7.39. Shares have lost 0.40% over the last five days, but have gained 46.34% over the last year to date. This security has underperformed the S&P 500 by 7.40% during the last year.

Key company metrics

  • Open(U.S.) $7.37
  • Previous close(U.S.) $7.36
  • High(U.S.) $7.46
  • Low(U.S.) $7.25
  • Bid / Ask(U.S.) $7.38 / (U.S.) $7.39
  • YTD % change+46.34%
  • Volume316,871
  • Average volume (10-day)1,098,244
  • Average volume (1-month)1,263,019
  • Average volume (3-month)1,516,136
  • 52-week range(U.S.) $2.80 to (U.S.) $8.30
  • Beta4.03
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.30
Updated July 29 11:25 AM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.10%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7643
Total other revenue--------
Total revenue7643
Gross profit5412
Total cost of revenue2241
Total operating expense30313529
Selling / general / administrative21222021
Research & development88118
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-23-25-31-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-41-38-31-27
Income after tax-41-38-31-27
Income tax, total0000
Net income-41-38-31-27
Total adjustments to net income--------
Net income before extra. items-41-38-31-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-41-38-31-27
Inc. avail. to common incl. extra. items-41-38-31-27
Diluted net income-41-38-31-27
Dilution adjustment--0----
Diluted weighted average shares106105105105
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.36-0.29-0.26
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.39-0.36-0.29-0.26